Study M709
Study name | Yang B 2019 |
Title | Clinical efficacy and biological regulations of omiga-3 PUFA-derived endocannabinoids in major depressive disorder |
Overall design | In this study, a 12-week double-blind, non-placebo, randomized controlled trial. Eighty-eight major depressive disorder (MDD) participants were randomly assigned to receive eicosapentaenoic acid (EPA group, 3.0 g/day), docosahexaenoic acid (DHA group, 1.4 g/day), or a combination of EPA and DHA (EPA + DHA group; EPA 1.5 g/d and DHA, 0.7 g/day). Eighty-five participants completed the trial, and their clinical remission (HAMD scores <= 7) and plasma PUFA-derived EC levels were measured. |
Study Type | Type2; Type4; |
Data available | Unavailable |
Organism | Human; |
Categories of depression | Depressive disorder; Depression; Depression; |
Criteria for depression | DSM-IV diagnosed MDD, HAMD-21 >= 18 |
Sample size | 85 |
Tissue | Peripheral; Blood; Plasma; |
Platform | MS-based; LC-MS: not reported; |
PMID | |
DOI | |
Citation | Yang B, Lin L, Bazinet RP, et al. Clinical efficacy and biological regulations of omiga-3 PUFA-derived endocannabinoids in major depressive disorder. Psychother Psychosom. 2019;88(4):215-224. |
Metabolite |
